VolitionRx Plans Partnership to Launch Cancer Dx Platform in China

Mar 28, 2019

|

NEW YORK (360Dx) — Belgian diagnostics firm VolitionRx announced today that it is planning a partnership with Shanghai Fosun Long March Medical Science to introduce its NuQ blood-based cancer diagnostic platform in China.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

VolitionRx Plans Partnership to Launch Cancer Dx Platform in China

To read the full story....

Breaking News

Biden Administration Funds $1B for COVID-19 Testing in Indian Country

Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

NIH Awards Qorvo Biotechnologies $24.4M for Rapid SARS-CoV-2 Antigen Test

In Brief This Week: Exact Sciences, Siemens Healthineers, Seegene, Agilent Technologies, and More

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

What's Popular?

4D Path Prepping FDA Submission for AI-Enabled Breast Cancer Digital Pathology Product

Grail Cancer Early Detection Test Performance Holds Steady as Q2 Launch Approaches

OncoDiag Taking Aim at Broader Adoption of Molecular Multiplex Test for Bladder Cancer Recurrence

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

Cancer Dx Firm C2i Genomics Raises $100M in Financing

Sponsorships